Over the past decade, non-coding RNA-based therapeutics have proven as a great potential
for the development of targeted therapies for cancer and other diseases. The discovery of …

Although chemotherapy is a first option in treatment of cancer patients, drug resistance has
led to its failure, requiring strategies to overcome it. Cancer cells are capable of switching …

Introduction Among conventional and novel therapeutic approaches, the siRNA strategy
stands out for treating disease by silencing the gene responsible for the corresponding …

Most anticancer drugs often fail in clinical trials due to poor solubility, poor bioavailability,
lack of targeted delivery and several off-target effects. Polymeric nanoparticles such as poly …

Five small interfering RNA (siRNA)-based therapeutics have been approved by the Food
and Drug Administration (FDA), namely patisiran, givosiran, lumasiran, inclisiran, and …

Pancreatic cancer (PC) is one of the leading causes of death and is the fourth most
malignant tumor in men. The epigenetic and genetic alterations appear to be responsible for …

Small interfering RNA (siRNA) delivery by nanocarriers has been identified as a promising
strategy in the study and treatment of cancer. Short nucleotide sequences are synthesized …

Nanotherapy has emerged as an improved anticancer therapeutic strategy to circumvent the
harmful side effects of chemotherapy. It has been proven to be beneficial to offer multiple …

Introduction Due to its unique functional impact on multiple cancer cell circuits including
proliferation, apoptosis, tumor dissemination, DNA damage repair, and immune response …

Cases of respiratory diseases have been increasing around the world, affecting the health
and quality of life of millions of people every year. Chronic respiratory diseases (CRDs) and …